120 related articles for article (PubMed ID: 38588566)
1. Hydroxychloroquine-induced pigmentation in rheumatic diseases: prevalence, clinical features and influencing factors.
Yin ZJ; Li P; Yu J; Zuo D; Fan H; Li F; Wang J; Gao F; Zhao W; Wang S; Ma S; Wang J
Rheumatology (Oxford); 2024 Apr; ():. PubMed ID: 38588566
[TBL] [Abstract][Full Text] [Related]
2. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.
Jallouli M; Francès C; Piette JC; Huong du LT; Moguelet P; Factor C; Zahr N; Miyara M; Saadoun D; Mathian A; Haroche J; De Gennes C; Leroux G; Chapelon C; Wechsler B; Cacoub P; Amoura Z; Costedoat-Chalumeau N;
JAMA Dermatol; 2013 Aug; 149(8):935-40. PubMed ID: 23824340
[TBL] [Abstract][Full Text] [Related]
3. Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases.
Bahloul E; Jallouli M; Garbaa S; Marzouk S; Masmoudi A; Turki H; Bahloul Z
Lupus; 2017 Oct; 26(12):1304-1308. PubMed ID: 28355984
[TBL] [Abstract][Full Text] [Related]
4. Hydroxychloroquine Does Not Increase the Risk of Cardiac Arrhythmia in Common Rheumatic Diseases: A Nationwide Population-Based Cohort Study.
Lo CH; Wei JC; Wang YH; Tsai CF; Chan KC; Li LC; Lo TH; Su CH
Front Immunol; 2021; 12():631869. PubMed ID: 33868251
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
[TBL] [Abstract][Full Text] [Related]
6. Retinal Toxicity in Patients Treated With Hydroxychloroquine: A Cross-Sectional Study.
Espandar G; Moghimi J; Ghorbani R; Pourazizi M; Seiri MA; Khosravi S
Med Hypothesis Discov Innov Ophthalmol; 2016; 5(2):41-46. PubMed ID: 28293646
[TBL] [Abstract][Full Text] [Related]
7. Possible relationship between hydroxychloroquine and electrocardiographic and echocardiographic abnormalities in patients with inflammatory rheumatic diseases--a monocentric study.
Pinheiro FO; Martins Carvalho M; Madureira P; Seabra Rato M; Macedo F; Costa L
Lupus; 2023 Mar; 32(3):388-393. PubMed ID: 36598483
[TBL] [Abstract][Full Text] [Related]
8. [Application and safety of hydroxychloroquine in chronic disease among children].
Sun L; Gong YR; Chen Q; Zhang T; Li GM; Liu HM; Yang CH; Qian LL; Li YF; Yao W; Xu H
Zhonghua Er Ke Za Zhi; 2021 Feb; 59(2):107-112. PubMed ID: 33548956
[No Abstract] [Full Text] [Related]
9. Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases.
Rekedal LR; Massarotti E; Garg R; Bhatia R; Gleeson T; Lu B; Solomon DH
Arthritis Rheum; 2010 Dec; 62(12):3569-73. PubMed ID: 20722019
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of hydroxychloroquine retinopathy with long-term use in a cohort of Indian patients with rheumatic diseases.
Manoj M; Sahoo RR; Singh A; Hazarika K; Bafna P; Kaur A; Wakhlu A
Rheumatol Int; 2021 May; 41(5):929-937. PubMed ID: 33704526
[TBL] [Abstract][Full Text] [Related]
11. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
[TBL] [Abstract][Full Text] [Related]
12. Hydroxychloroquine safety: A meta-analysis of randomized controlled trials.
Eljaaly K; Alireza KH; Alshehri S; Al-Tawfiq JA
Travel Med Infect Dis; 2020; 36():101812. PubMed ID: 32645478
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and Potential Risk Factors of Hydroxychloroquine Retinopathy in Patients with Systemic Lupus Erythematosus: Focusing on Asian Population.
Kao JH; Lai TT; Lu CH; Lan TY; Hsieh YT; Shen CY; Li KJ; Hsieh SC
J Ocul Pharmacol Ther; 2022 Dec; 38(10):728-733. PubMed ID: 36206015
[No Abstract] [Full Text] [Related]
14. Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study.
Cairoli E; Danese N; Teliz M; Bruzzone MJ; Ferreira J; Rebella M; Cayota A
Lupus; 2015 Oct; 24(11):1204-9. PubMed ID: 25852050
[TBL] [Abstract][Full Text] [Related]
15. Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus.
Fasano S; Messiniti V; Iudici M; Coscia MA; Ciccia F
Lupus Sci Med; 2023 Jan; 10(1):. PubMed ID: 36631164
[TBL] [Abstract][Full Text] [Related]
16. Targets Exploration of Hydroxychloroquine for Pigmentation and Cell Protection Effect in Melanocytes: The Clue for Vitiligo Treatment.
Xie B; Chen Y; Hu Y; Zhao Y; Luo H; Xu J; Song X
Drug Des Devel Ther; 2022; 16():1011-1024. PubMed ID: 35411132
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis.
Lenfant T; Salah S; Leroux G; Bousquet E; Le Guern V; Chasset F; Francès C; Morel N; Chezel J; Papo T; Cacoub P; Mouthon L; Guettrot-Imbert G; Cohen P; Régent A; Mauget-Faÿsse M; Piette JC; Jallouli M; Costedoat-Chalumeau N;
Rheumatology (Oxford); 2020 Dec; 59(12):3807-3816. PubMed ID: 32442312
[TBL] [Abstract][Full Text] [Related]
18. Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study.
Jung SY; Kim MS; Kim MC; Choi SH; Chung JW; Choi ST
Clin Microbiol Infect; 2021 Apr; 27(4):611-617. PubMed ID: 33316402
[TBL] [Abstract][Full Text] [Related]
19. A Preliminary Study on the Therapeutic Effects of Hydroxychloroquine on Generalized Vitiligo.
Sazgarnia S; Layegh P; Darchini-Maragheh E; Sepehr V; Meshkat M; Fathi-Najafi S; Rahsepar S
Acta Dermatovenerol Croat; 2022 Nov; 30(3):146-150. PubMed ID: 36812271
[TBL] [Abstract][Full Text] [Related]
20. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
Singh B; Ryan H; Kredo T; Chaplin M; Fletcher T
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013587. PubMed ID: 33624299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
